Abstract
Activation of the fibroblast growth factor receptor (FGFR) signaling pathway is commonly involved in carcinogenesis,1 and oncogenic molecular alterations in the FGFR pathway occur across various tumor types.2 Agents that target FGFR have been demonstrated to inhibit tumor growth and angiogenesis—and, in some cases, to reverse acquired resistance to anticancer agents—in patients with FGFR alterations in urothelial carcinoma,3,4 cholangiocarcinoma,5 glioblastoma,6 and non–small-cell lung cancer (NSCLC).7 Here, we present the first report, to our knowledge, of a patient with head and neck squamous cell carcinoma (HNSCC) with FGF amplifications who achieved a complete response to an FGFR inhibitor.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
